PCCTC Studies
The PCCTC’s trial portfolio represents a substantial proportion of industry-sponsored and NIH-sponsored prostate cancer trials open in the US, characterizing a substantial presence in this research space. Our studies span the entire prostate cancer disease continuum and are strategically aligned with the Consortium’s own pathway-based scientific programs and a parallel commitment to the co-development of trial endpoints and biomarkers. Patient advocacy efforts are supported by Your Prostate Cancer. Help.
Featured Studies
IRONMAN: International Registry for Men With Advanced Prostate Cancer (NCT03151629)
PROMISE Registry: A Prostate Cancer Registry of Outcomes and Germline Mutations for Improved Survival and Treatment Effectiveness (NCT04995198)
TALENT: A Study of Talazoparib with or Without Enzalutamide in People with Prostate Cancer Who Have Previously Received Abiraterone Acetate (NCT06844383)
Active Study Portfolio
A Phase I/II Trial of Concurrent Chemohormonal Therapy Using Enzalutamide (MDV-3100) and Cabazitaxel in Patients with Metastatic Castration Resistant Prostate Cancer (NCT02522715)
ARN-509 + Abiraterone acetate + Leuprolide with Stereotactic, Ultra-Hypofractionated Radiation (AASUR) in Very High-Risk Prostate Cancer: A Single Arm, Phase II Study (NCT02772588)
A Randomized Phase II Trial of Abiraterone, Olaparib, or Abiraterone + Olaparib in Patients with Metastatic Castration-Resistant Prostate Cancer with DNA Repair Defects (NCT03012321)
IRONMAN: International Registry for Men with Advanced Prostate Cancer (NCT03151629)
PRODIGY: Observational study to describe effectiveness of olaparib in subjects with metastatic castration-resistant prostate cancer who have failed prior treatment with a new hormonal agent and carry selected homologous recombination repair gene mutations (An IRONMAN Registry Substudy)
EMPRO: Engaging Men in Patient Reported Outcomes (An IRONMAN Registry Substudy)
CUETIP: Clinical Utility of an AI-Enabled PSMA-Targeted Imaging Biomarker in Prostate Cancer (An IRONMAN Registry Substudy)
BIOGUARD: BIOmarker landscape in GU cancers: Assessment in the Real-worlD (An IRONMAN Registry Substudy)
IRONSeq: Characterizing the whole genome landscape of the IRONMAN Registry (An IRONMAN Registry Substudy)
Phase III Trial of Docetaxel vs. Docetaxel and Radium-223 for Metastatic Castration-Resistant Prostate Cancer (NCT03574571)
Metacure: Multi-arm Multi-modality Therapy for Very High Risk Localized and Low Volume Metastatic Prostatic Adenocarcinoma (NCT03436654)
A Phase II Study of Carboplatin, Cabazitaxel and Abiraterone in High Volume Metastatic Castration Sensitive Prostate Cancer (CASCARA) (NCT03934840)
A Single-arm, Phase 2 Study to Evaluate the Safety and Efficacy of IMMU-132 in Patients with Castration-Resistant Prostate Cancer Progressing on Enzalutamide or Abiraterone (NCT03725761)
A Phase Ib/II Study of Intermittent Talazoparib Plus Temozolomide in Subjects with Metastatic Castration Resistant Prostate Cancer and No Mutations in DNA Damage Repair (NCT04019327)
An open-label Phase I/IIa study to evaluate the safety and efficacy of CCS1477 as monotherapy and in combination in patients with advanced solid/metastatic tumours (NCT03568656)
Single Arm Phase II Study of Abiraterone + Atezolizumab + Lupron and Stereotactic Body Radiotherapy (SBRT) to the Prostate in Men with Newly Diagnosed Hormone-sensitive Metastatic Prostate Cancer (NCT04262154)
A Phase 2 Multicohort Study of Nivolumab in Combination with Docetaxel and Androgen Deprivation Therapy in Metastatic Hormone Sensitive Prostate Cancer Patients with DNA Damage Repair Defects or Inflamed Tumors (NCT04126070)
PROMISE: A Prostate Cancer Registry of Outcomes and Germline Mutations for Improved Survival and Treatment Effectiveness (NCT04995198)
An open-label Phase I/IIa study to evaluate the safety and efficacy of CCS1477 as monotherapy in patients with advanced haematological malignancies (NCT04068597)
DASL-HiCaP: Darolutamide Augments Standard Therapy for Localised Very High-Risk Cancer of the Prostate (ANZUP1801). A randomised phase 3 double-blind, placebo-controlled trial of adding darolutamide to androgen deprivation therapy and definitive or salvage radiation in very high risk, clinically localised prostate cancer (NCT04136353)
Neoadjuvant darolutamide and abemaciclib in high-risk prostate cancer (NCT05617885)
A Phase 1b/2 Study Evaluating the Activity of Tinengotinib (TT–00420) in Combination with Androgen Receptor Signaling Inhibitors (ARSIs) in Patients with Metastatic Castration Resistant Prostate Cancer (NCT06457919)
TALazoparib with or without ENzaluTamide in patients with metastatic castration-resistant prostate cancer and HRR mutations after progression on abiraterone acetate (TALENT) (NCT06844383)
A Phase 1/2a, Multicenter, Open-Label, First in Human Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of DB-1311 in Subjects with Advanced/Metastatic Solid Tumors (NCT05914116)
A Phase 1b/2a, Multicenter, Open-Label Study of Pocenbrodib as Monotherapy and in combination With Abiraterone Acetate, Olaparib, or 177Lu-PSMA-617 in Participants with Metastatic Castration-Resistant Prostate Cancer (mCRPC) (NCT06785636)
Phase 1, Dose-Escalation Study of KTX2001 (an NSD2 Inhibitor) Alone and in Combination With Darolutamide for Metastatic Castration-Resistant Prostate Cancer (STRIKE-001) (NCT07103018)